Arcturus Therapeutics Holdings Inc.
ARCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARCT
Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing mRNA-based therapeutics and vaccines, including programs for cystic fibrosis and ornithine transcarbamylase deficiency, with a marketed vaccine (KOSTAIVE) approved in Europe and the UK.
Key risk: Capital need uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$431.7M
Cash Runway
29.3 moLead Asset
ARCT-032 (Phase 2)
Next Catalyst
Phase2_Start · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials · 1 catalyst for Arcturus Therapeutics Holdings Inc..
Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing mRNA-based therapeutics and vaccines, including programs for cystic fibrosis and ornithine transcarbamylase deficiency, with a marketed vaccine (KOSTAIVE) approved in Europe and the UK.
- Cash and equivalents of $193.5M as of June 30, 2026 [sec].
- Total revenue of $3.0M and net loss of $23.8M for the six months ended June 30, 2026 [sec].
- No debt outstanding as of March 31, 2026 after terminating its revolving credit agreement [sec_mda · as of 2026-05-07].
- KOSTAIVE (COVID-19 vaccine) approved by the European Commission in February 2025 and by the United Kingdom in January 2026 [sec_mda · as of 2026-03-03].
- Phase 2 trial of ARCT-810 (LUNAR-OTC candidate) ongoing and Phase 2 study of ARCT-032 (CF candidate) enrollment expected to continue [sec_mda · as of 2026-05-07][news · published 2026-08-06].
What works
- KOSTAIVE received regulatory approval from the European Commission and the UK, validating the platform with major regulatory authorities [sec_mda · as of 2026-03-03].
- The company has no debt outstanding as of March 31, 2026, providing financial flexibility [sec_mda · as of 2026-05-07].
- Cash position of $193.5M as of June 30, 2026 is expected to fund operations through at least the next twelve months [sec_mda · as of 2026-08-06].
What to weigh
- The company expects to continue generating losses and will require additional capital to fund long-term operations [sec_mda · as of 2026-08-06].
- Future capital requirements are difficult to forecast and depend on many factors outside the company's control [sec_mda · as of 2026-08-06].
- If additional financing is not available on acceptable terms, the company may need to scale back or discontinue product development [sec_mda · as of 2026-03-03].
From the filings
Quoted directly from source documents.
Cash position sufficient for at least 12 months
“We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months”
SEC MD&A · August 6, 2026
No debt outstanding
“the Company had no debt outstanding as of March 31, 2026”
SEC MD&A · May 7, 2026
KOSTAIVE regulatory approvals
“KOSTAIVE was approved by the European Commission (EC) in February 2025 and by the United Kingdom in January 2026”
SEC MD&A · March 3, 2026
Need for additional capital
“we will require additional capital to fund our operations in order to support our long-term plans”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-09-01 · Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity — Initiation of a Phase 2 trial for ARCT-032, an inhaled mRNA therapy for cystic fibrosis.
Risks & what to watch (3)›
Key risks
- Capital need uncertainty — Future capital requirements are difficult to forecast and depend on many factors outside the company's control [sec_mda · as of 2026-08-06].
- Dependence on partnerships — Achievement of milestones under strategic alliances is a key factor for funding [sec_mda · as of 2026-03-03].
- Clinical trial risks — Success of pipeline candidates (ARCT-032, ARCT-810) is uncertain and may affect financial position [news · published 2026-08-06].
What to watch
- Phase 2 start for ARCT-032 (CF) on September 1, 2026 [upcoming catalysts].
- Progress of ARCT-810 (LUNAR-OTC) Phase 2 trial [sec_mda · as of 2026-05-07].
- Any updates on CSL Seqirus collaboration or BARDA agreement [sec_mda · as of 2026-05-07].
- Cash burn rate and potential need for additional financing [sec_mda · as of 2026-08-06].
Sources: News · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Arcturus Therapeutics Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arcturus Therapeutics Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
29.3 months
D/E 0.31 · 0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$177.6M
| Holder | Shares | Value |
|---|---|---|
| federated hermes, inc. | 3,303,640 | $25.5M |
| ark investment management llc | 2,769,518 | $21.4M |
| blackrock, inc. | 2,613,281 | $20.2M |
| amova asset management americas, inc. | 2,288,935 | $17.6M |
| vanguard capital management llc | 2,214,040 | $17.1M |
| two sigma investments, lp | 1,081,784 | $8.4M |
| vanguard portfolio management llc | 977,922 | $7.5M |
| geode capital management, llc | 660,928 | $5.1M |
| state street corp | 543,863 | $4.2M |
| millennium management llc | 478,557 | $3.7M |
Showing top 10 of 125 institutional holders of Arcturus Therapeutics Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 28.2%
- Days to cover
- 15.5
- Shares short
- 6,441,740
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arcturus Therapeutics Holdings Inc.?
Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing mRNA-based therapeutics and vaccines, including programs for cystic fibrosis and ornithine transcarbamylase deficiency, with a marketed vaccine (KOSTAIVE) approved in Europe and the UK.
What is Arcturus Therapeutics Holdings Inc.'s lead drug candidate?
Arcturus Therapeutics Holdings Inc.'s most advanced tracked candidate is ARCT-032 (Phase 2) for Cystic Fibrosis.
What is Arcturus Therapeutics Holdings Inc.'s next catalyst?
Arcturus Therapeutics Holdings Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity " — expected September 1, 2026.
Who is the CEO of Arcturus Therapeutics Holdings Inc.?
Mr. Joseph E. Payne M.Sc. is the chief executive officer of Arcturus Therapeutics Holdings Inc. (ARCT).
Where is Arcturus Therapeutics Holdings Inc. headquartered?
Arcturus Therapeutics Holdings Inc. (ARCT) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.